CYP19A1 and breast carcinoma: In metastatic hormone receptor-positive and HER2-negative breast cancer, the currently enrolling single arm phase Ib/II dose escalation clinical trial combines TTI-101 with standard of care palbociclib and aromatase inhibitor upon progression of disease.